English EN Spanish ES French FR Chinese (Simplified) ZH-CN
Print Friendly, PDF & Email

NCT/Study#

NCT03397706 /

VT3996-201

A Phase 1b/2 Open-Label, Dose Escalation And Expansion Study Of Orally Administered Vrx-3996 And Valganciclovir In Subjects With Epstein-Barr Virus-Associated Lymphoid Malignancies

DISEASE GROUP:
Lymphoma
current phase:
Phase I/II
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: